Complete report @ http://goo.gl/Eim8Ye "Mavrilimumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023" Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

1. Mavrilimumab Market Analysis and Forecast to 2023
By
GlobalData
Browse More Reports On Life Sciences @
http://www.rnrmarketresearch.com/reports/life-sciences .
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Single User License: US $3495
Published: Dec 2014

2. Mavrilimumab Market Analysis and Forecast to 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and
deformity of the joints. It affects over seven million individuals in the 10MM covered in this
report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the
prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs
have been effective in treating the signs and symptoms of RA and inhibiting progression to
erosive bone disease. However, the landscape is quickly changing with the introduction of
biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which
will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely
effective therapies for RA, the market is extremely competitive for new entrants and will
undergo further pressure as biosimilars are approved and launch.
Complete report available @ http://www.rnrmarketresearch.com/mavrilimumab-
rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

3. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by
MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha
subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and
synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the
activation, differentiation, and recruitment of macrophages and neutrophils in the damaged
and inflamed joints of RA patients.
Scope
• Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Mavrilimumab including product description, safety and efficacy
profiles as well as a SWOT analysis.
• Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Purchase a Copy of this Report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023

4. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust
return.
• Stay ahead of the competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of
Mavrilimumab performance.
• Obtain sales forecast for Mavrilimumab from 2013-2023 in top 6 countries (the US, France,
Germany, Italy, Spain and the UK).
Inquire for discount on this Report @
http://www.rnrmarketresearch.com/contacts/discount?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023

5. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Table of Contents
• 1 Table of Contents 5
• 2 Introduction 10
• 3 Disease Overview 15
• 4 Disease Management 22
• 5 Competitive Assessment 40
• 6 Unmet Need and Opportunity 42
• 7 Pipeline Assessment 54
• 8 Mavrilimumab 62
• 9 Appendix 68
• List of Tables
• List of Figures
Inquire for sample of this report @ http://www.rnrmarketresearch.com/contacts/request-
sample?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023

6. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Related Market Reports:
PharmaPoint: Rheumatoid Arthritis – Japan Drug Forecast and Market Analysis to 2023
research report is now available with RnRMarketResearch.com @
http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-japan-drug-forecast-
and-market-analysis-to-2023-market-report.html
Rituxan/Mabthera (rituximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to
2023 research report is now available with RnRMarketResearch.com @
http://www.rnrmarketresearch.com/rituxanmabthera-rituximab-rheumatoid-arthritis-
forecast-and-market-analysis-to-2023-market-report.html
Mavrilimumab Market Analysis and Forecast to 2023

7. For more details contact Mr. Ritesh Tiwari: sales@rnrmarketresearch.com /
+18883915441
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports
by leading market research publishers across the globe.
Mavrilimumab Market Analysis and Forecast to 2023